

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No. *125*
RDID00111US

In Re Application Of: SALAMONE, Salvatore J.

Serial No.

09/712,525

Filing Date

November 14, 2000

Examiner

To Be Assigned

Group Art Unit

1614

Title: IMMUNOASSAY FOR HIV PROTEASE INHIBITORS

Address to:

Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RDID00011US

In Re Application: SALAMONE, Salvatore J.

Serial No.

09/712,525

Filing Date

November 14, 2000

Examiner

To Be Assigned

Group Art Unit

1614

IMMUNOASSAY FOR HIV PROTEASE INHIBITORS



Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 02-2958 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Marilyn Amick
Signature

Dated:

July 22, 2002

Marilyn L. Amick, Reg. No. 30,444
Roche Diagnostics Corporation
9115 Hague Road, Bldg. D
P.O. Box 50457
Indianapolis, IN 46250-0457
Telephone : (317) 521-7561
Facsimile: (317) 521-2883

CC:

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY DOCKET NO.

RDID00111

SERIAL NO.

09/712,525

SALAMONE, Salvatore J.

FILING

November 14, 2000

GROUP

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
32	4	4,134,792	01/79	Boguslaski et al.	195	99	
32	5	6,107,852	08/00	Dorn	435	25	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

6	✓	Mansfeld, Hans-Werner et al., "Detection of inhibition of HIV-1 protease activity by an enzyme-linked immunosorbent assay (ELISA)," Journal of Immunological Methods, 161 (1993) 151-155
7	✓	Poirier, Jean-Marie et al., "Simultaneous Determination of the Five HIV-Protease Inhibitors: Amprenavir, Indinavir, Nelfinavir, Ritonavir, and Saquinavir in Human Plasma by Solid-Phase Extraction and Column Liquid Chromatography," Therapeutic Drug Monitoring, Vol. 22, No. 4, 465-473, 2000

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

RDID001111

Application Number

09/712/525

Applicant(s)

SALAMONE, Salvatore J.

Filing Date

November 14, 2000

Group Art Unit

1614

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

8

Sarubbi, Edoardo et al., "A high throughput assay for inhibitors of HIV-1 protease Screening of microbial metabolites," FEBS Letters, Vol. 279, No. 2, 265-269, February 1991

9

Wiltshire, H.R. et al., "Chromatographic and Immunochemical Approaches to the Analysis of the HIV Protease Inhibitor Saquinavir in Plasma," Analytical Biochemistry 281, 105-114 (2000)

10

Yn, Sung-Liang et al., "Assay of HIV-1 protease activity by use of crude preparations of enzyme and biotinylated substrate," Journal of Virological Methods 53 (1995) 63-73

JUL 22 2002

PATENT & TRADEMARK

JUL 22 2002

PATENT & TRADEMARK

RECEIVED

JUL 26 2002

TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

07-23-02

16/24

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

Applicant(s): SALAMONE, Salvatore J.

Docket No.

RDID00111US

Serial No.

09/712,525

Filing Date

November 14, 2000


Examiner

To Be Assigned

Group Art Unit

164

Invention: IMMUNOASSAY FOR HIV PROTEASE INHIBITORS



RECEIVED
JUL 22 2002
TECH CENTER 1600/2900

I hereby certify that this Supplemental Information Disclosure Statement

(Identify type of correspondence)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under

37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on

July 22, 2002
(Date)

Michele Wilson
(Typed or Printed Name of Person Mailing Correspondence)

Michele Wilson
(Signature of Person Mailing Correspondence)

EL841983671US

("Express Mail" Mailing Label Number)

Note: Each paper must have its own certificate of mailing.